TipRanks
Advertisement
Advertisement
Kyntra Earns Buy Rating on Strong Cash Runway and Multiple Late-Stage Clinical Catalysts
PremiumRatingsKyntra Earns Buy Rating on Strong Cash Runway and Multiple Late-Stage Clinical Catalysts
29d ago
Kyntra Bio reports Q2 EPS $2.96, consensus ($3.18)
Premium
The Fly
Kyntra Bio reports Q2 EPS $2.96, consensus ($3.18)
1M ago
Kyntra Bio Confronts Nasdaq Listing Risk as Asset and Revenue Shortfall Threatens Global Select Status
Premium
Company Announcements
Kyntra Bio Confronts Nasdaq Listing Risk as Asset and Revenue Shortfall Threatens Global Select Status
1M ago
KYNB Earnings Report this Week: Is It a Buy, Ahead of Earnings?
PremiumPre-EarningsKYNB Earnings Report this Week: Is It a Buy, Ahead of Earnings?
1M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100